Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kang-ai Injection
- Development stage
- Preclinical
- Lead developer
- Jilin Changbaishan Pharmaceutical Group
- Administration
- Intravenous
01
Overview
Kang-ai Injection (KAI) is a Traditional Chinese Medicine (TCM) injection derived from a combination of extracts from Astragalus (milkvetch root), Ginseng, and Sophora flavescens (Kushen). It is authorized and widely used in China as an adjuvant therapy for various cancers, including hepatocellular carcinoma, non-small cell lung cancer, and colorectal cancer. KAI is known for its beneficial effects such as enhancing immune function, reducing side effects of chemotherapy, and improving chemotherapy sensitivity. Its proposed mechanisms of action involve inhibiting tumor cell proliferation, invasion, and metastasis, inducing tumor cell apoptosis, and modulating specific signaling pathways like PI3K-AKT and IL-6/STAT3.
- Other names
- Kang AiKAIKA
02
Targets
Tumor necrosis factor receptor 2 (TNFR2)/Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (AKT)/Nuclear factor kappa B (NF-κB) axisRB1 (Retinoblastoma-associated Protein)CCND1 (Cyclin D1)CDKN1A (Cyclin-dependent kinase inhibitor 1A)
Beyond the preview
Go deeper on Kang-ai Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kang-ai Injection.